Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy

Diabetes Research and Clinical Practice

Volumn 71, Issue 1, 2006, Pages 45-51

  Sampson, Mike ^a   Wall, Steven ^b   Baugh, Mark ^a,b   Worley, Jo ^a,b   Davies, Isabel ^a,c   Hughes, David ^c   Gavrilovic, Jelena ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c INSTITUTE OF FOOD RESEARCH   (United Kingdom)

Author keywords

ADAM metalloproteinases; Aspirin; Matrix metalloproteinases; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOCONCENTRATION; HUMAN; HUMAN CELL; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADAM PROTEINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 29244448691     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.05.014     Document Type: Article

References (38)

1. P. Libby, U. Schoenbeck, F. Mach, A.P. Selwyn, and P. Ganz Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilisation Am. J. Med. 104 1998 145 185
2. Z.S. Galis, G.K. Sukhova, M.W. Lark, and P. Libby Increased expression of matrix metallo proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J. Clin. Invest. 94 2001 2493 2503
3. H. Nagase, and J.F. Woessner Jr. Matrix metalloproteinases J. Biol. Chem. 274 1999 21491 21494
4. Y. Zhang, K. McCluskey, K. Fujii, and L.M. Wahl Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and -independent mechanisms J. Immunol. 161 1998 3071 3076
5. X.P. Xu, S.R. Meisel, J.M. Ong, S. Kaul, B. Cercek, and T.B. Rajavashisth Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages Circulation 99 1999 993 998
6. S. Uemura, H. Matsushita, W. Li, A.J. Glassford, T. Asagami, and K.H. Lee Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress Circ. Res. 88 2001 1291 1298
7. A.K. Death, E.J. Fisher, K.C. McGrath, and D.K. Yue High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes Atherosclerosis 168 2003 263 269
8. S.J. Wall, M.J. Sampson, N. Levell, and G. Murphy Elevated matrix metalloproteinase 2 and 3 from human diabetic dermal fibroblasts Br. J. Dermatol. 149 2003 13 16
9. M.D. Baugh, J. Gavrilovic, I.R. Davies, D.A. Hughes, and M.J. Sampson Monocyte matrix metalloproteinase production in type 2 diabetes and controls - a cross sectional study Cardiovasc. Diabetol. 10 2 2003 3
10. M. Bzowska, N. Jura, A. Lassak, R.A. Black, and J. Bereta Tumour necrosis factor-α stimulates expression of TNF-α converting enzyme in endothelial cells Eur. J. Biochem. 271 2004 2808 2820
11. K.J. Garton, P.J. Gough, J. Philalay, P.T. Wille, C.P. Blobel, and R.H. Whitehead Stimulated shedding of vascular cell adhesion molecule 1 [VCAM-1] is mediated by tumor necrosis factor-α-converting enzyme [ADAM-17] J. Biol. Chem. 278 2003 37459 37464
12. D.R. Goddard, R.A. Bunning, and M.N. Woodroofe Astrocyte and endothelial cell expression of ADAM-17 [TACE] in adult human CNS Glia 34 2001 267 271
13. C.W. Franzke, K. Tasanen, H. Schacke, Z. Zhou, K. Tryggvason, and C. Mauch Transmembrane collagen-XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs EMBO J. 21 2002 5026 5035
14. L.C. Bridges, K.R. Hanson, P.H. Tani, T. Mather, and R.D. Bowditch Integrin-α 4β1-dependent adhesion to ADAM-28 [MDC-L] requires an extended surface of the disintegrin domain Biochemistry 42 2003 3734 3741
15. K. Esposito, F. Nappo, R. Marfella, G. Giugliano, F. Giugliano, and M. Ciotola Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress Circulation 106 2002 2067 2072
16. M. Sampson, I. Davies, J. Gavrilovic, B. Sussams, J. Brown, and S. Astley Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in type 2 diabetes Cardiovasc. Diabetol. 3 2004 7
17. V. Roldan, F. Marin, G.Y. Lip, and A.D. Blann Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature Thromb. Haemost. 90 2003 1007 1020
18. E. Leinonen, E. Hurt-Camejo, O. Wiklund, L.M. Hulten, A. Hiukka, and M.R. Taskinen Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes Atherosclerosis 166 2003 387 394
19. P. Mehta Aspirin in the prophylaxis of coronary artery disease Curr. Opin. Cardiol. 17 2002 552 558
20. E. Karna, and J.A. Palka Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation Eur. J. Pharmacol. 443 2002 1 6
21. S. Murono, T. Yoshizaki, H. Sato, H. Takeshita, M. Furukawa, and J.S. Pagano Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein-1 through suppression of matrix metalloproteinase-9 expression Cancer Res. 60 2000 2555 2561
22. M.C. Jiang, C.F. Liao, and P.H. Lee Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells Biochem. Biophys. Res. Commun. 282 2001 671 677
23. M.V. Gomez-Gaviro, I. Gonzalez-Alvaro, C. Dominguez-Jimenez, J. Peschon, R.A. Black, and F. Sanchez-Madrid Structure function relationship and role of tumor necrosis factor-α-converting enzyme in the down-regulation of l-selectin by non-steroidal anti-inflammatory drugs J. Biol. Chem. 277 2002 38212 38221
24. D.A. Hughes, P.J. Townsend, and P.L. Haslam Enhancement of the antigen presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis Clin. Exp. Immunol. 87 1992 279 286
25. P.J. Koshy, C.J. Lundy, A.D. Rowan, S. Porter, D.R. Edwards, and A. Hogan The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction Arthritis Rheum. 46 2002 961 967
26. S. Devaraj, and I. Jialal Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation Circulation 102 2000 191 196
27. M.J. Sampson, I.R. Davies, S. Braschi, K. Ivory, and D.A. Hughes Increased expression of a scavenger receptor [CD36] in monocytes from subjects with type 2 diabetes Atherosclerosis 167 2003 129 134
28. M.J. Sampson, I.R. Davies, J.C. Brown, K. Ivory, and D.A. Hughes Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients Arterioscler. Thromb. Vasc. Biol. 22 2002 1187 1193
29. W. Mattos, S. Lim, R. Russell, A. Jatakanon, K.F. Chung, and P.J. Barnes Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids Chest 122 2002 1543 1552
30. G.P. Ladwig, M.C. Robson, R. Liu, M.A. Kuhn, D.F. Muir, and G.S. Schultz Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers Wound Repair Regen. 10 2002 26 37
31. H. Senzaki, S. Masutani, J. Kobayashi, T. Kobayashi, H. Nakano, and H. Nagasaka Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease Circulation 104 2001 860 863
32. Y.Z. Fan, J.T. Zhang, H.C. Yang, and Y.Q. Yang Expression of MMP-2, TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance World J. Gastroenterol. 8 2002 1138 1143
33. P.K. Chua, M.E. Melish, Q. Yu, R. Yanagihara, K.S. Yamamoto, and V.R. Nerurkar Elevated levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 during the acute phase of Kawasaki disease Clin. Diagn. Lab. Immunol. 10 2003 308 314
34. A. Kalela, T.A. Koivu, T. Sisto, J. Kanervisto, M. Hoyhtya, and P. Sillanaukee Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease Scand. J. Clin. Lab. Invest. 62 2002 337 342
35. S. Blankenberg, H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, and G. Hafner Plasma concentrations and genetic variation of matrix metalloproteinase-9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
36. H. Kai, H. Ikeda, H. Yasukawa, M. Kai, Y. Seki, and F. Kuwahara Peripheral blood levels of matrix metalloproteases-2 and 9 are elevated in patients with acute coronary syndrome J. Am. Coll. Cardiol. 32 1998 368 372
37. K.K. Koh, J.Y. Ahn, D.K. Jin, S.H. Han, H.S. Kim, and I.S. Choi Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidaemia Int. J. Cardiol. 97 2004 239 244
38. M.H. Tayebjee, G.Y. Lip, A.D. Blann, and R.J. Macfadyen Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP-1 and TIMP-2) Thromb. Res. 2005 205 210